Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Core Scientific, Inc./txCORZ · Entity 389 | Director | September 15, 2026 | September 17, 2026 |
| Nakamoto Inc.NAKA · Entity 6621 | Director | August 14, 2025 | October 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Core Scientific, Inc./tx
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 265,262 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Purchase · Acquired 6,000 · Balance 265,262 |
Nakamoto Inc.
Report date August 14, 2025 · Filed October 07, 2025
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 17, 2026 20:26 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | PurchaseCommon Stock | 6,000 | $16.33 | $97,980.00 |
DisclosureSEC source: 0000905148-26-004212 · form4.xml · nonDerivative · entry 1 Weiss Eric Stanton · CIK 0002009491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,262 Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:13 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | PurchaseCommon Stock | 7,000 | $19.19 | $134,358.00 |
DisclosureSEC source: 0000905148-26-003841 · form4.xml · nonDerivative · entry 1 Weiss Eric Stanton · CIK 0002009491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,262 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.785 to $19.595, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range. Read SEC document |
| March 09, 2026 Filed Mar 10, 2026 20:08 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | PurchaseCommon Stock | 7,000 | $14.53 | $101,699.50 |
DisclosureSEC source: 0000905148-26-001220 · form4.xml · nonDerivative · entry 1 Weiss Eric Stanton · CIK 0002009491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,262 Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 21:11 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 18,575 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000550 · form4.xml · nonDerivative · entry 1 Weiss Eric Stanton · CIK 0002009491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,262 F1 · shares: Represents a restricted stock unit ("RSU") grant. The RSUs will vest in full on February 3, 2027, provided that the Reporting Person continues to provide service to the Issuer as a non-employee director on such date. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:25 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | PurchaseCommon Stock | 5,000 | $21.50 | $107,500.00 |
DisclosureSEC source: 0000905148-25-003803 · form4.xml · nonDerivative · entry 1 Weiss Eric Stanton · CIK 0002009491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,687 Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 21:34 UTC | Nakamoto Inc. NAKA · Entity 6621 | GrantCommon Stock | 112,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-091243 · ownership.xml · nonDerivative · entry 1 Weiss Eric Stanton · CIK 0002009491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,781 F1 · shares: This reflects restricted stock units ("RSUs") that vest on August 15, 2026 (the "Vesting Date"), subject to the reporting person's continued services on the board of directors of the issuer through the Vesting Date. Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 20:07 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | PurchaseCommon Stock | 6,000 | $8.46 | $50,750.40 |
DisclosureSEC source: 0000905148-25-000880 · form4.xml · nonDerivative · entry 1 Weiss Eric Stanton · CIK 0002009491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,687 Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 00:12 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 20,448 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000234 · form4.xml · nonDerivative · entry 1 Weiss Eric Stanton · CIK 0002009491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,687 F1 · shares: Represents a restricted stock unit ("RSU") grant. The RSUs will vest in full on January 27, 2026, provided that the Reporting Person continues to provide service to the Issuer as a non-employee director on such date. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 20:18 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | PurchaseCommon Stock | 5,000 | $9.21 | $46,050.00 |
DisclosureSEC source: 0000905148-24-002535 · form4.xml · nonDerivative · entry 1 Weiss Eric Stanton · CIK 0002009491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,239 Read SEC document |
| May 27, 2024 Filed May 29, 2024 00:07 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 47,793 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001644 · form4.xml · nonDerivative · entry 2 Weiss Eric Stanton · CIK 0002009491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,239 F2 · shares: Represents an RSU grant. The RSUs will vest in full on January 23, 2025, provided that the Reporting Person continues to provide service to the Issuer as a non-employee director on such date. Read SEC document |
| May 27, 2024 Filed May 29, 2024 00:07 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 127,446 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001644 · form4.xml · nonDerivative · entry 1 Weiss Eric Stanton · CIK 0002009491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,446 F1 · shares: Represents a restricted stock unit ("RSU") grant. The RSUs will vest in full on January 23, 2027, provided that the Reporting Person continues to provide service to the Issuer as a non-employee director on such date. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 23:46 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | PurchaseCommon Stock | 15,000 | $3.03 | $45,396.00 |
DisclosureSEC source: 0000905148-24-000973 · form4.xml · nonDerivative · entry 1 Weiss Eric Stanton · CIK 0002009491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · price: The price reported is a weighted average price. These shares of common stock were purchased in multiple transactions at prices ranging from $3.02 to $3.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock purchased at each separate price within such range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.